A5013742395- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Immune cells in cancer
- Breast Cancer Treatment Studies
- Cell Adhesion Molecules Research
- Advanced Biosensing Techniques and Applications
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Nanoplatforms for cancer theranostics
- HER2/EGFR in Cancer Research
- Single-cell and spatial transcriptomics
- Atherosclerosis and Cardiovascular Diseases
- Neutropenia and Cancer Infections
- Monoclonal and Polyclonal Antibodies Research
- Radiomics and Machine Learning in Medical Imaging
- Virus-based gene therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Peripheral Neuropathies and Disorders
- Lung Cancer Treatments and Mutations
- Global Cancer Incidence and Screening
- Colorectal and Anal Carcinomas
- Cancer Treatment and Pharmacology
Long Island University
2021-2024
NYU Langone Health
2020-2024
Columbia University Irving Medical Center
2016-2023
New York University
2019-2022
Winthrop-University Hospital
2019-2021
Island Hospital
2021
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2021
Columbia University
2017-2019
Texas Health Dallas
2018
New York Oncology Hematology
2018
Novel methods to analyze the tumor microenvironment (TME) are urgently needed stratify melanoma patients for adjuvant immunotherapy. Tumor-infiltrating lymphocyte (TIL) analysis, by conventional pathologic methods, is predictive but insufficiently precise clinical application. Quantitative multiplex immunofluorescence (qmIF) allows evaluation of TME using multiparameter phenotyping, tissue segmentation, and quantitative spatial analysis (qSA). Given that CD3+CD8+ cytotoxic lymphocytes (CTLs)...
3010 Background: PF-07104091 is a novel CDK2-selective inhibitor under investigation in pts with selected advanced or metastatic solid tumors. We present the first disclosure of data from first-in-human, multicenter, phase 1 study monotherapy (NCT04553133). Methods: Pts HR+/HER2- advanced/metastatic breast cancer (mBC) who received ≥ 2 lines treatment for mBC including prior endocrine therapy (ET) + CDK4/6 inhibitors (CDK4/6i), and other tumors, were included. Prior fulvestrant chemotherapy...
Background: Anal squamous cell carcinoma (ASCC) incidence has been rising over the past decade, most dramatically in HIV-positive men who have sex with (MSM). We aimed to identify a novel in-office approach for ablating high-grade anal intraepithelial neoplasia (HGAIN), believed precursor lesion ASCC. Materials and Methods performed retrospective analysis of medical records from New York City surgical practice, identifying patients HGAIN treated electrocautery ablation (ECA) followed at...
<h3>Background</h3> Immunotherapy, in particular checkpoint blockade, has changed the clinical landscape of metastatic melanoma. Nonetheless, majority patients will either be primary refractory or progress over follow up. Management progressing on first-line immunotherapy remains challenging. Expanded treatment options with combination demonstrated efficacy previously unresponsive to single agent alternative therapy. <h3>Case presentation</h3> We describe case a patient diffusely melanoma,...
Abstract Patients with resected stage II-III melanoma have approximately a 35% chance of death from their disease. A deeper understanding the tumor immune microenvironment (TIME) is required to stratify patients and identify factors leading therapy resistance. We previously identified that profile (MIP), an IFN-based gene signature, ratio CD8+ cytotoxic T lymphocytes (CTL) CD68+ macrophages both predict disease-specific survival (DSS). Here, we compared primary metastatic tumors found nuclei...
Abstract Purpose: Biomarkers are needed to stratify patients with stage II–III melanoma for clinical trials of adjuvant therapy because, while immunotherapy is protective, it also confers the risk severe toxicity. We previously defined and validated a 53-immune gene immune profile (MIP) predictive both distant metastatic recurrence disease-specific survival (DSS). Here, we test MIP on third independent population. Experimental Design: A retrospective cohort 78 primary was analyzed using...
Background: The PI3K/Akt/mTOR pathway in part impacts tumorigenesis through modulation of host immune activity. To assess the effects Akt inhibition on tumor micro-environment (TME), we analyzed tissue from patients with operable hormone receptor positive, HER2 negative breast cancer (BC) treated a presurgical trial inhibitor MK-2206. Methods: Quantitative multiplex immunofluorescence (qmIF) was performed using CD3, CD8, CD4, FOXP3, CD68, and pancytokeratin biopsy surgical specimens MK-2206...
1092 Background: ORIN1001 is a first-in-class small molecule targeting novel enzyme with unique mode of inhibition that selectively blocks the Inositol Requiring Enzyme 1α (IRE1) RNAse and X-Box Binding Protein 1 (XBP1) activation in endoplasmic reticulum. now undergoing Phase 1/2 clinical testing advanced solid tumors. Methods: In dose escalation trial (3+3 design), was administered PO daily as single agent patients (pts) tumors combination Abraxane pts relapsed, refractory breast cancer....
TPS621 Background: Clinical trials have been an invaluable tool in providing improvements the discovery, treatment, and quality of life for various diseases disorders including breast cancer, which impacts millions people each year. Historically, patient trial populations not racially diverse due to several factors such as bias, healthcare distrust, access, eligibility criteria. However, current efforts are focused on improving diversity inclusion promote efficacy health equity across all...
Response to talimogene laherparepvec (T-Vec) is difficult assess as pigmented macrophages that have ingested melanoma cells (‘melanophages’) persist after injection, mimicking melanoma. We used quantitative immunofluorescence (qIF) (1) distinguish melanophages from in biopsies two patients treated with T-Vec and (2) evaluate the tumor microenvironment pretreatment posttreatment. Tissues were stained 4’,6-diamidino-2-phenylindole, cluster of differentiation (CD) 3, CD8, CD68, human leukocyte...
1513 Background: In high-risk estrogen-receptor positive, HER2 or triple negative breast cancer (BC), chemotherapy can increase cure rates in early-stage disease and prolong survival setting of advanced disease. Real world data specific to BC is needed counsel patients (pts) with on their risk for SARS-CoV-2 infection mortality the context pandemic. Methods: this retrospective study, we abstracted clinical including demographics, tumor histology, treatment, COVID-19 testing results status...
Abstract BACKGROUND: MammaPrint is a gene expression signature used to determine the risk of distant recurrence for patients with early-stage breast cancer. Previous studies from MINDACT, FOCUS, IKA, and STO-3 trials have demonstrated that postmenopausal node-negative UltraLow Risk tumors are considered indolent excellent long-term survival outcomes up 20 years little no endocrine treatment. These suggest ideal candidates treatment optimization which has resulted in inclusion result NCCN...
Abstract Metastatic breast cancer poses significant clinical challenge, necessitating improved treatment options. Immune checkpoint blockade approval for PD-L1+ triple-negative highlights potential durable response. However, PD-L1 diagnostics can be discordant and responses in low/negative patients emphasize the need deeper understanding of tumor microenvironment (TME). In a single center phase II trial, specimens were obtained from 70 at baseline, cycle 1 featuring monotherapy using...
9570 Background: Uveal melanoma (UM) is a rare subset of that resistant to immune checkpoint blockade. High density macrophages (Mϕ) and TILs associated with poor prognosis in primary UM but little known about the tumor microenvironment (TME) metastatic (MUM). Here we performed quantitative spatial analysis using multiplex immunohistochemistry (mIHC) characterize TME MUM, compare MUM cutaneous (MCM), identify potential mechanisms resistance immunotherapy. Methods: We identified pts untreated...
Background: Abnormal blood glucose (BG) levels during hematopoietic cell transplantation (HCT) are associated with increased infections, delayed engraftment, and prolonged hospitalization, though little is known about these associations. Materials Methods: We retrospectively evaluated mean BG in the week prior to HCT subsequent outcomes for 852 HCTs at our hospital from 1/2009 – 12/2013 pertaining 745 patients. Outcomes included infections (pneumonia, C. difficile, positive cultures,...